Eric L. Cramer

Eric L. Cramer, a shareholder, concentrates his practice on complex antitrust litigation, including prosecuting antitrust cases with a particular focus in recent years on the pharmaceutical and medical device industries.  Mr. Cramer has also taken leading roles in cases concerning a wide variety of other industries and markets, including representing a proposed class of independent truck stops in a case regarding the market for trucker fleet cards.

Over the past decade, Mr. Cramer has been substantially responsible for recovering a combined total of more than $1 billion in antitrust cases on behalf of classes of direct purchasers of the following drugs, among others: Cardizem CD, Buspirone, Platinol, Terazosin, Relafen, Ovcon, Tricor, and Remeron. Each of these cases charged one or more pharmaceutical manufacturers with improperly impeding the entry of less expensive generic competitors in violation of the federal antitrust laws.

Mr. Cramer began his career representing victims of human radiation experimentation carried out by the federal government in conjunction with state and private actors as part of the United States atomic weapons program during the Cold War. He helped resolve two such cases for over $4.7 million combined, and was principally responsible for a reversal by the Ninth Circuit Court of Appeals of a summary judgment dismissal of one of those cases on statute of limitations grounds. See Bibeau, et al. v. Pacific Northwest Research Foundation, et al., 188 F.3d 1105 (9th Cir. 1999).

Mr. Cramer is significantly involved in bettering his community in the area of public education, having been actively involved as litigation counsel for the Independence Charter School.  After a successful appeal to the Pennsylvania Charter School Appeal Board, which granted the school a charter, Mr. Cramer secured an affirmance by the Commonwealth Court. See School District of Philadelphia v. Independence Charter School, 2001 Pa. Commw. LEXIS 279 (May 3, 2001). The Center City Philadelphia charter school opened its doors to nearly three-hundred elementary age school children in the Fall of 2001 and continues to thrive today.

Mr. Cramer is a frequent speaker at conferences and symposia on issues involving antitrust, public policy, the pharmaceutical industry, and complex litigation more generally.